drugset / Trial / NCT01269242
The Effects of Bindarit in Preventing Stent Restenosis
RandomizedParallel-groupTriple-blindPrevention
Summary
The main study objective is to assess the efficacy and safety of different bindarit dosages compared to placebo in preventing restenosis, in patients submitted to coronary stenting and using a bare metal stent (Vision BMS, by Abbott).
Timeline
- Start
- 2009-01
- Primary completion
- 2011-01
- Completion
- 2011-04
Drugs
| Evaluation | Drug | Modality | Dose | Route |
|---|---|---|---|---|
| Subject | Bindarit | Small molecule | 600 mg | — |
| Subject | Bindarit | Small molecule | 1200 mg | — |